With effect from December 28, 2022, the paid subscription shares in AlzeCure Pharma AB will be traded on First North Premier Growth Market. Trading will continue until further notice. Instrument: Paid subscription shares Short name: ALZCUR BTA 2 Clearing: Bilateral settlement at Euroclear Sweden ISIN code: SE0019354051 Order book ID: 278756 Market Segment: First North STO Tick Size: MiFID II tick size table For further information concerning this exchange notice please contact Issuer Surveillance , telephone +46 8 405 70 50, or iss@nasdaq.com
Nasdaq Stockholm AB: Listing of paid subscription shares of AlzeCure Pharma AB (698/22)
© 2022 GlobeNewswire
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.03. | AlzeCure Pharma: AlzeCure Achieves Last Patient Last Visit in its Phase II Clinical Trial of the Non-Opioid ACD440 in Neuropathic Pain | STOCKHOLM, SWEDEN / ACCESSWIRE / March 13, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) a pharmaceutical company that develops a broad portfolio of drug candidates... ► Artikel lesen | |
| 07.03. | AlzeCure Pharma: AlzeCure Participates at Redeye Alzheimer Seminar on March 15 | STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: AlzeCure Publishes its Year-end Report for January - September 2022 | STOCKHOLM, SWEDEN / ACCESSWIRE / February 24, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January -... ► Artikel lesen | |
| 31.01. | AlzeCure's neuropathic pain candidate study reaches crucial phase | ||
| 31.01. | AlzeCure Pharma: Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440 | STOCKHOLM, SE / ACCESSWIRE / January 31, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) a pharmaceutical company that develops a broad portfolio of drug candidates... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
